Effectiveness of a pharmacist-driven intervention in chronic obstructive pulmonary disease

Effectiveness of a pharmacist-driven intervention in chronic obstructive pulmonary disease (EPIC): a pragmatic cluster randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78138190

Enrollment

140

Registered

2016-03-04

Start date

2016-05-01

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease Respiratory Chronic obstructive pulmonary disease, unspecified

Interventions

We will compare pharmacies delivering an improved form of care that focuses on COPD management with pharmacies providing the care they would normally offer on a daily basis. Multifact

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Physician-diagnosed COPD 2. Age =40 years at trial enrollment 3. Sufficient ability to answer questionnaires in English

Exclusion criteria

Exclusion criteria: 1. A known Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) of <30% 2. A diagnosis of dementia or a prescription for cholinesterase inhibitors 3. A terminal illness 4. Physician-diagnosed asthma 5. Participation in another clinical trial 6. If they do not provide consent

Design outcomes

Primary

Measure	Time frame
Change from baseline to 6 months in medication adherence using the medication possession ratio (MPR) and the Morisky Medication Adherence Scale (MMAS-8)	—

Secondary

Measure	Time frame
1. Proportion of patients with a clinically significant change in adherence 2. Proportion of patients defined as having ‘good adherence’ 3. Mean MPR between groups 4. Quality of life as measured by the St. George’s Respiratory Questionnaire 5. Medication inhalation technique using a pharmacist-scored checklist 6. Healthcare resource utilization 7. Antibiotic and oral corticosteroid use for COPD exacerbations Measured at baseline and 6 months.	—

Measure

Time frame

1. Proportion of patients with a clinically significant change in adherence 2. Proportion of patients defined as having ‘good adherence’ 3. Mean MPR between groups 4. Quality of life as measured by the St. George’s Respiratory Questionnaire 5. Medication inhalation technique using a pharmacist-scored checklist 6. Healthcare resource utilization 7. Antibiotic and oral corticosteroid use for COPD exacerbations Measured at baseline and 6 months.

—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 12, 2026